Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 41.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,137 shares of the medical research company’s stock after buying an additional 2,085 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in EXACT Sciences were worth $375,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Crow Point Partners LLC purchased a new stake in EXACT Sciences in the 4th quarter worth approximately $145,000. Oppenheimer Asset Management Inc. lifted its position in EXACT Sciences by 2,925.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after buying an additional 3,072 shares in the last quarter. SG Americas Securities LLC purchased a new stake in EXACT Sciences in the 3rd quarter worth approximately $183,000. Appleton Group LLC purchased a new stake in EXACT Sciences in the 4th quarter worth approximately $220,000. Finally, Crescent Grove Advisors LLC purchased a new stake in EXACT Sciences in the 3rd quarter worth approximately $200,000. Institutional investors own 83.12% of the company’s stock.
In related news, insider Kevin T. Conroy sold 134,057 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 101,488 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the completion of the transaction, the insider now owns 931,540 shares in the company, valued at $42,590,008.80. The disclosure for this sale can be found here. Insiders have sold a total of 764,182 shares of company stock worth $40,574,047 in the last 90 days. 4.00% of the stock is owned by insiders.
EXAS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research report on Tuesday, January 16th. Canaccord Genuity upgraded shares of EXACT Sciences to a “buy” rating and set a $60.00 target price for the company in a research report on Tuesday, October 31st. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Leerink Swann reiterated an “outperform” rating and issued a $63.00 target price (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Finally, Bank of America set a $67.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a research report on Monday, January 8th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. EXACT Sciences has a consensus rating of “Buy” and a consensus price target of $52.84.
TRADEMARK VIOLATION WARNING: “EXACT Sciences Co. (EXAS) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/18/exact-sciences-co-exas-shares-bought-by-zurcher-kantonalbank-zurich-cantonalbank.html.
EXACT Sciences Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.